Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Interim Results in Ongoing GLP-1 Human Pilot Study

  • Lexaria, a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing GLP-1 human pilot study
  • The study seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide
  • Lexaria’s DehydraTECH GLP-1 showed a 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group
  • The DehydraTECH GLP-1 group also only saw a 5.3% spike in glucose levels after having a standardized meal at the 240-minute mark and a snack at the 360-minute mark, compared to 22.7% for the control group

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing human pilot study that seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide. The study, which focused on Rybelsus(R), a commercially available semaglutide drug, involved seven healthy subjects, four of whom received the DehydraTECH GLP-1, with the other three receiving the control (https://cnw.fm/kr4Ic).

Of note was DehydraTECH GLP-1’s 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group. These results were achieved in the initial 100 minutes of taking the drugs, and at all but the 20-minute and 240-minute sample time points, the DehydraTECH GLP-1 blood glucose levels were reduced more than evidenced by the control group. More so, even 24 hours after dose administration, the blood glucose levels were reduced in the DehydraTECH GLP-1 group by 6.3% relative to baseline. In contrast, that of the control group was only reduced by 0.67%. This evidenced a nearly ten-fold improvement with DehydraTECH GLP-1.

When the subjects were permitted to eat a standardized meal at the 240-minute mark and a standardized snack at the 360-minute mark, glucose levels spiked by 22.7% for the control group, while those in the DehydraTECH GLP-1 group only saw a 5.3% rise. Although this cannot be attributed to DehydraTECH GLP-1’s overall efficacy in achieving sustained blood glucose reduction, it is a plausible explanation for the difference and a pointer to the overall potential of the technology.

While there are still some additional steps to be taken, these positive results are welcome and point to the technology’s potential, specifically in diabetes treatment. In the DIAB-A22-1 animal study, Lexaria demonstrated at least three positive outcomes, which included weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels. The study also demonstrated an improvement in locomotor activity compared to untreated obese control rats, with no severe health concerns during dosing (https://cnw.fm/2BAmL).

With the results from Lexaria’s DehydraTECH GLP-1, the company is on track to replicate the positive results from its diabetes study. More importantly, it is on track to carve out a decent market share in an industry projected to bring between $150 billion and $200 billion a year (https://cnw.fm/eV0fW). By doing so, it will also ensure that GLP-1 drugs are more effective with reduced side effects while also being accessible to individuals living with diabetes. It also hopes it will improve the quality of life of people living with the condition by offering a less intrusive and less painful treatment alternative than what is currently in the market.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — German Lawmakers to Vote on Revised Cannabis Legalization Measure Next Week

Legislators in Germany have decided to revise a bill to legalize cannabis in the country, a week before they cast their final vote on it in parliament. The bill to legalize marijuana is being championed by Health Minister Karl Lauterbach, who first discussed details concerning the revised legalization measure in April 2022. In May of the same year, he presented the legislative text to cabinet officials.

When responding to early criticism of the measure from law enforcement and medical groups, Lauterbach emphasized that marijuana reform would be implemented together with a campaign to educate the public on the risks of using marijuana. Last week, Kirsten Kappert-Gonther of the Green Party stated that the resolution would be revised in ways that would make it better.

The amendments would relax some provisions that were challenged by advocates and supporters in the Bundestag. After the resolution is amended, individuals found possessing between 25–30 grams of marijuana won’t automatically be treated as criminal offenders but as administrative violators. The possession limit for home-grown cannabis will also be increased to 30 grams from 25 grams.

With regard to public consumption of marijuana, individuals will not be allowed to use marijuana within 100 meters distance of a school. Prior to the amendment, this figure stood at 200 meters. Legislators also agreed that social clubs that could distribute cannabis to members may begin launching in July 2024 while home cultivation and possession of marijuana legal for adults would begin in April of next year.

Kristine Lütke, a member of the Free Democratic Party in the Bundestag, added that these revisions could bring relief to consumers and make the bill even better. In addition, legislators plan to introduce a complementary resolution that would create pilot programs for commercial sales in different cities across Germany.

Currently, it is expected that once the Bundestag approves the legalization bill, the measure may be advanced to the Bundesrat. In September of this year, members of the Bundesrat had tried and failed to block the proposed measure.

While the Federal Cabinet approved the measure’s initial framework last year, the government thought it best to receive approval from the European Union before enacting it, so they were sure they wouldn’t be violating any global obligations.

In other news, government officials from some countries, including America, met in Germany this previous week to discuss global cannabis policy issues. Last  year, Narcotics Drugs Commissioner Burkhard Blienert and a group of German legislators visited the United States and toured marijuana businesses in California to help inform their approach to legalization.

When the German cannabis market finally opens, there will be a chance for local companies grow to the levels seen by enterprises such as Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) that are operating in mature marijuana markets.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Missouri Companies Sell Cannabis Products Worth $1B in 2023

Missouri’s cannabis industry has surpassed $1 billion in sales of medical and recreational marijuana products for the year 2023, as disclosed by the state’s Department of Health and Senior Services (DHHS). In October alone, retailers transacted approximately $95.5 million in recreational cannabis products and an additional $17.6 million in medical cannabis.

Although these figures reflect a slight decrease compared to the previous month, they contribute to the overall 2023 sales, pushing the state’s total marijuana revenue beyond $1.1 billion.

The trajectory of adult-use cannabis sales has exhibited a gradual increase since the commencement of sales in February. Conversely, the sales of medical cannabis have experienced a consistent decline. Notably, there has been a reduction in the number of registered medical cannabis patient cultivators, caregivers and patients throughout the year.

Cumulatively, all cannabis sales in Missouri since 2020 amount to $1.7 billion, according to the DHHS. These figures are, however, approximations, deviating from the conventional reporting format of most states, as Missouri’s DHHS rounds the numbers to the nearest $100,000.

As part of the state’s utilization of tax revenue, lawmakers recently announced the allocation of $17 million to support veterans’ drug treatment, health and legal aid initiatives.

Missouri’s cannabis industry has encountered significant challenges this year, including the recall of thousands of marijuana products due to the alleged illegal use of hemp-derived cannabinoids from outside Missouri. Regulators moved to revoke the business license of Delta Extraction, a company central to the incident. This development raised concerns, particularly regarding practices at product testing labs, which had faced criticism earlier in the year for alleged lab shopping to achieve higher THC potency numbers.

The state, however, rescinded the recall of nearly 15,000 products last month, allowing the products to be returned to dispensary shelves after a storage mandate since early August. The state’s marijuana regulator stated last month that a review of product-tracking records confirmed some recalled marijuana products contained THC sourced exclusively from Missouri’s regulated market.

Moreover, a cannabis retailer, Point Management, operating as Shangri-La, Columbia, recently settled a dispute with a union, resolving 15 charges of unfair labor practices. The settlement mandates the reinstatement of five employees and requires the retailer to compensate more than $145,000 in back pay, front pay, interest and damages for direct or foreseeable financial harm to 10 employees.

In a separate development, legislators criticized the state’s marijuana regulators for exceeding their authority in setting new rules on product branding and packaging aimed at reducing appeal to children.

The booming sales registered in Missouri may depict the broad success that established cannabis companies such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) are enjoying in the markets in which they operate.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — AMA Study Contradicts Claims That Drug Overdose Prevention Centers Fuel Crime

New research has found that overdose prevention centers in New York City have not led to an increase in crime. This is despite concerns that the establishment of harm-reduction centers would cause crime to skyrocket. The new findings add to previous research that demonstrated the centers’ potential in decreasing overdose deaths.

Overdose-prevention centers allow individuals to use illegal substances in a supervised environment, helping reduce the risk of harms associated with drug use, such as a fatal overdose.

The study was carried out by researchers at Brown University, the University of Pennsylvania and the University of Connecticut. For their research, the investigators examined crime trends in NYC’s first government-sanctioned overdose prevention centers, which were launched two years ago. They then compared their findings to areas close to more than 15 syringe service programs that did not provide resources to prevent overdose.

The researchers also analyzed 311 and 911 calls, drug-possession arrests, public nuisances, law enforcement summons for criminal infractions and medical events. They observed no considerable increases in calls for emergency services or crimes recorded by law enforcement in neighborhoods where the prevention centers were located.

In addition, they recorded no statistically significant spike in either violent or property crime near these overdose prevention centers. This is despite a reduction in the number of drug-possession arrests made as the state continues to reprioritize law enforcement.

In their report, the researchers stated that statistically significant decreases in narcotics enforcement by the police around these centers was observed, adding that this was consistent with NYC’s commitment to ensuring that individuals could access the centers without any interference by the police. The researchers also noted that more studies were needed to establish that overdose-prevention centers wouldn’t be linked to localized increases in disorder and crime in the long-term.

At the moment, however, the findings strengthen arguments from harm-reduction advocates on the minimal risk associated with using overdose-prevention sites to help alleviate the risk of overdose deaths, as the opioid crisis rages on.

The research’s findings were published by the American Medical Association in “JAMA Public Health.”

A separate study published in 2022 determined that trained staff intervened in more than 100 overdose instances two months after the first overdose prevention center was launched in NYC. The staff are said to have alleviated risks of overdose by administering oxygen and naloxone as well as offering other services to prevent death. Naloxone is a medication that has been approved by the FDA to reverse an opioid overdose.

The positive role that overdose-prevention centers are playing, contrary to the views of detractors, may mirror the positive impact that marijuana companies such as SNDL Inc. (NASDAQ: SNDL) are having in spite of prohibitionists’ alarmist claims that legalizing cannabis does more harm than good to society.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Study Finds Cannabis Gives Anxiety Sufferers Better Sleep Compared to Alcohol

A recent study supported by federal funding has uncovered insights into the sleep patterns of individuals dealing with anxiety, revealing that the use of marijuana appears to be linked to improved sleep quality. The research, published in the “Drug and Alcohol Review” journal and conducted collaboratively by teams from the University of Haifa, Colorado State University and the University of Colorado, sought to explore the subjective sleep experiences of 347 individuals utilizing cannabis to manage anxiety.

Over a span of 30 days, participants were engaged in daily surveys where they documented their substance use and recounted their previous night’s sleep experience. The study compared outcomes on days with no substance use, marijuana-only use, alcohol-only use and co-use of both substances.

The findings indicated a notable difference in reported sleep quality, with participants reporting better sleep on marijuana-only days and co-use days in contrast to nonuse days. Intriguingly, alcohol-only use did not exhibit a similar positive association with sleep quality. The study also revealed a correlation between the frequency of alcohol and cannabis use and sleep patterns. Individuals with higher usage frequencies reported enhanced sleep quality on days when marijuana was the sole substance used compared to those who used alcohol and cannabis less frequently.

This correlation challenges the idea that tolerance may diminish the sleep-inducing effects of cannabis, as the study suggests an opposite trend of improved sleep quality with more frequent marijuana use. In addition, contrary to the common belief that alcohol aids in sleep, the research corroborated previous findings that alcohol does not contribute significantly to overall sleep quality, especially when juxtaposed with cannabis.

The study posited that understanding various cannabis combinations and ratios remains limited, emphasizing the need for further research, especially in clinical trials. The inclusion of diverse cannabis types, varying in dosage and product selection, prompted the researchers to acknowledge existing gaps in knowledge, advocating for future trials to address these uncertainties.

The study concluded by emphasizing the urgency of experimental investigations into the effects of cannabis and alcohol on sleep. It underscored the potential positive impact of cannabis on subjective sleep quality for individuals dealing with anxiety. Additionally, it highlighted the need for further exploration into the interplay between the frequency of substance use and its immediate influence on sleep, especially in populations seeking cannabis as a coping mechanism for anxiety, where alcohol and cannabis misuse may be prevalent.

As the health benefits of cannabis gain more attention from the scientific community, demand could grow much faster, which could in turn boost the demand for ancillary services such as those offered by Innovative Industrial Properties Inc. (NYSE: IIPR).

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Building a Global Presence with Superior Delivery Technology for Wide Range of Drugs and Active Pharmaceutical Ingredients

  • Lexaria, a global innovator in drug delivery platforms, has, through its patented DehydraTECH(TM) technology, proven to enhance the performance of several categories of fat-soluble active molecules and drugs
  • Since 2018, human clinical studies on the technology have yielded positive results, ultimately earning Lexaria 37 granted patents globally, with many more pending around the world
  • With the strides made so far, Lexaria looks to grow its revenue and commercial opportunities through licensing

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains committed to its mission to provide healthier delivery methods of drugs and other Active Pharmaceutical Ingredients (“APIs”). This is made possible through its patented drug delivery technology, DehydraTECH(TM), proven to enhance the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats.

The company’s efforts have focused on several key segments, including hypertension, diabetes, antivirals, epilepsy, nicotine replacement, and more. This has been an ongoing process since 2016, with positive results achieved from various clinical studies thus far, showing up to 17x brain absorption improvements for oral administration of APIs. In 2021, for instance, the nicotine oral mucosal animal absorption study, NIC-A21-1, demonstrated a 10x to 20x reduction in time to deliver peak levels of nicotine, as well as a 1.7x to 6.6x improvement in nicotine levels in the bloodstream (https://cnw.fm/7orZ4).

This is enabled by DehydraTECH’s specific design for formulating and delivering lipophilic drugs and APIs. By increasing their effectiveness and improving the way they enter the bloodstream, DehydraTECH can offer a wide range of benefits, such as a significant increase in bioavailability, increased brain absorption, improving the speed of onset, masking unwanted tastes, and reduced drug administration costs.

Human clinical studies have been conducted since 2018, with more on the way, ultimately earning Lexaria 37 granted patents globally, with many more pending around the world. From 2018 to 2022, four human clinical studies on the potential treatment of hypertension were completed, evidencing lower blood pressure (“BP”) with zero serious adverse events. Lexaria is now closer than ever to submitting its Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial with the U.S. Food and Drug Administration.

For the first half of the 2023 calendar year, animal studies on using DehydraTECH-processed CBD for potentially treating diabetes demonstrated positive results such as reduced triglyceride levels, weight loss, and improved cholesterol levels. . .

“This is a remarkable achievement that speaks to the capabilities of the DehydraTECH technology and also to the Lexaria R&D team, working ardently with scarce resources relative to global multi-billion-dollar behemoths,” noted Chris Bunka, Lexaria’s CEO (https://cnw.fm/xOuDJ).

With the strides made, Lexaria looks to grow its revenue and commercial opportunities through licensing. Given its versatile application areas, the technology can be licensed by both the consumer-packaged goods industry and the drug and pharmaceutical sector. Its suitability cuts across a growing range of consumer product formats, such as registered drugs, nutraceuticals, oral suspensions, topical applications, capsules, pills, tablets and more.

The progress achieved thus far by Lexaria is remarkable. Its goals are also much more significant, as evidenced by the time and resources invested into DehydraTECH development. The efforts so far affirm the company’s commitment to providing healthier delivery methods for drugs and other APIs. They also assert its commitment to creating shareholder value and stamping its position as a leader in its segment.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Amid Congressional Inaction, NY Governor Enacts Measure Easing Cannabis Banking

Last week, Governor Kathy Hochul of New York signed into law a measure that eases the process through which financial institutions can work with legal marijuana businesses. The bill was sponsored by Assembly member Crystal Peoples-Stokes and Senator Jeremy Cooney.

It permits the Office of Cannabis Management to offer information about legal cannabis business applicants or licensees to financial institutions. The objective is to make it easier for businesses to comply with antimoney-laundering laws and filing of activity reports required for every marijuana-related transaction at the federal level.

It should be noted that before information can be shared, applicants and licensees would have to give their consent.

A memo attached to the measure states that it would permit financial institutions to access and verify financial as well as personal information for their prospective marijuana clients. It explains that the measure will reduce the costs imposed by additional reporting and compliance measures while also making it easier for financial institutions that want to bank marijuana businesses to comply with federal reporting.

The memo also highlights that handling large cash amounts, which most legal marijuana businesses do because they are unable to secure banking services, puts workers as well as the general public at risk. It notes that accessing financial services affects public safety and that cash businesses are exploited for criminal purposes, which undermines the goal of creating legal, safe and regulated markets.

The memo also highlights that handling large cash amounts, which most legal marijuana businesses do because they are unable to secure banking services, puts workers as well as the general public at risk. It notes that accessing financial services affects public safety and cash businesses are exploited for criminal purposes, which undermines the goal of creating legal, safe and regulated markets.

Currently, marijuana is still classified as a Schedule I substance under the Controlled Substances Act. Despite being legal in various states, this classification makes the drug illegal at the federal level.

In addition to providing banking services to marijuana businesses, the new law eliminates a number of the systemic and financial barriers that can prevent some from taking part in the legal cannabis market safely. Expanding eligibility for participation in this flourishing market may facilitate the opening of more legal businesses at a time when the illicit market continues to flourish in New York City.

Hochul also signed a resolution that offers tax relief to cannabis businesses in the state of New York. Currently, these businesses are still not allowed to make federal deductions under IRS code 280E.

In other news, legislators in Albany have been debating on solutions to deal with issues facing the implementation of marijuana legalization. Last month, the legislators discussed enforcement efforts to quash the illegal cannabis market in the state, the THC potency tax, preventing youth from accessing marijuana and lab testing practices, priorities on licensing and distribution, among other problems.

As more states take matters into their own hands and enact local measures to help marijuana businesses access conventional banking services, the operations of numerous entities such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) could have one less hurdle to deal with.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Marijuana-Infused Dinners on the Rise in Maryland

The marijuana industry in the state of Maryland is on course to becoming a billion-dollar business after the recreational use of the drug was legalized a few months ago. Many are taking advantage of this new market, with some offering private dinner parties that feature foods infused with marijuana.

One entrepreneur, Chef Jazmine Moore, has been offering such course meals at her restaurant. Moore believes more individuals are looking for alternative ways to relax and enjoy themselves, and her food affords them an approachable way to use marijuana.

Her approach is backed by numbers from a recent poll, which show that almost 40% of individuals in America felt two alcoholic drinks was unhealthy, which may have some substituting drinks for marijuana.

The chef normally consults with her guests prior to every event, which enables her to ensure that everyone participating is aged 21 years and older; she also ensures that every individual signs a waiver. Moore revealed that she had used marijuana herself to help her overcome Crohn’s Disease symptoms, which had caused digestive issues that actually prevented her from eating.

Moore’s business, the Green Panther Chef, allows her to forge her path in a new field while also taking away the stigma that still surrounds the use of cannabis. During her dinner parties, which last roughly three hours, guests often begin the night with a CBD-infused mocktail or cocktail.

One dinner guest, Shirdell Kenney, revealed that marijuana helped people unwind and afforded the space for guests to fully immerse themselves in the experience. Ayanna Lawson, another dinner guest, noted that consuming marijuana-infused meals didn’t make one a stoner. Lawson herself owns and manages Front Row Travels, a travel firm that centers on marijuana-friendly getaways and experiences.

A few other guests were interviewed, with one declaring that food did taste better with marijuana while another discussed how marijuana helped her as a survivor of thyroid cancer.

Moore revealed that she enjoyed teaching others how to cook with marijuana and had already published her own cookbook focused on that topic. She hopes that in the future, cannabis will be allowed to expand restaurant menus in the state. When asked about marijuana’s effect after one has consumed infused foods, she equates the feeling to that of having a few glasses of wine.

Kenney herself noted that the feeling was a mellow and better high, especially when compared to smoking a joint.

Such dinners featuring marijuana-infused foods and drinks could go a long way in helping many individuals become comfortable consuming marijuana products from entities similar to Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) that make products for the recreational and medical markets within different jurisdictions.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – AROYA Unveils CLIMATE ONE, TEROS ONE and AROYA GO at MJBizCon

AROYA by Addium, the preferred cannabis production platform for more than 600 operators across the country, from booth #51005 at MJBizCon in Las Vegas, introduced the latest additions to its portfolio: The CLIMATE ONE Climate Station and The TEROS ONE Substrate Sensors. AROYA’s new environmental and substrate sensors are a means through which to access real-time information and to adjust irrigation and climate conditions. The combination lets growers control environmental factors to influence plant growth patterns and outcomes, leading to more effective and sustainable cultivation practices. “AROYA has set a new standard in precision agriculture for cannabis,” said AROYA CEO Scott Campbell. “These devices are not just technological advancements; they’re a game-changer for growers who are committed to sustainable and efficient cultivation practices. These announcements embody our commitment to empowering cultivators with the best sensors, software and science – the requisite tools for success.”

In addition, the company introduced AROYA GO, the most advanced cannabis grow kit to ever hit the consumer market. AROYA GO brings the company’s industry-leading sensors, data science, intelligence and weather station technology to at-home and craft cannabis cultivation. With the same high-grade hardware, elegant software and real-time analytics used in the world’s largest and most advanced grow rooms, plug-and-play AROYA GO democratizes the ability to cultivate top-quality, high-yield craft cannabis. “AROYA GO is a legitimate game-changer for serious, passionate enthusiasts,” Campbell said of the system.

To view the full press releases, visit https://cnw.fm/sr3aW and https://cnw.fm/Z7UP6

About AROYA

AROYA is the leading cannabis production platform, combining forward-thinking science, sensors and software to empower cultivators with data-driven insights that help them increase yield, scale operations and achieve consistent quality. Based in Pullman, Washington, AROYA brings 30 years of experience in sensor development to the ag-tech industry, enabling cultivators to do more with less while making more purpose-driven decisions for their businesses. For additional information, please visit AROYA.io.

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Genomic Study Gives Insights into Why Individuals Suffer from CUD

An examination of the genetic makeup of more than a million individuals, spearheaded by researchers at Yale, has provided valuable insights into the biological foundations of marijuana use disorder and how it relates to mental health issues, substance misuse (including tobacco) and potentially even a higher risk of lung cancer.

The study examined the genomes of participants from a range of ancestry groups, utilizing information from many genomic databases in addition to the extensive genetic data bank of the United States Veterans Affairs’ Million Veteran Program (MVP).The analysis revealed many genetic variations connected to marijuana use disorder, providing insight into a range of behavioral and physical problems related to the condition.

The study, published in the “Nature Genetics Journal” this month, was led by Daniel Levy, an assistant professor of psychiatry, and Joel Gelernter, a professor at the Foundations Fund of Psychiatry and Genetics and Neuroscience.

According to the Centers for Disease Control and Prevention (CDC), 48 million individuals, or 18% of the American population, used cannabis at least once in 2019, making cannabis the most widely used federally illegal substance in the country. Previous research indicates that roughly 10% of cannabis users develop an addiction, while three out of ten users have a marijuana use disorder, which is defined as an unfavorable pattern of use that results in clinical impairment or suffering. Furthermore, another study found that those who began using marijuana throughout childhood or adolescence and who use it more regularly have a higher chance of developing the disorder.

The newly unveiled genetic findings provide nuanced views into the underpinnings of this phenomenon and its potential ramifications on health. Notably, certain genetic variants associated with marijuana use disorder were identified in genes responsible for encoding three distinct types of neuron receptors, indicating an elevated risk of developing this disorder.

Intriguingly, there was a correlation found between these same genetic variations and an elevated risk of lung cancer. The researchers, however, underscore the necessity for further investigation to disentangle the influences of tobacco smoking and other factors on cancer diagnosis from those associated with cannabis use.

Joel Gelernter emphasized the significance of this study, labeling it the most extensive genome-wide exploration of marijuana use disorder to date. He also noted that as cannabis legalization and decriminalization efforts gain momentum across states, studies of this nature are instrumental in comprehending the accompanying health risks.

This study helps to clarify that individuals who develop cannabis use disorder often have a genetic predisposition to this condition. For that reason, most members of the general population can safely use marijuana products from any of the many companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) for recreational or medical reasons without having a high risk of developing CUD.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN